On January 5, the Food and Drug Administration (FDA) authorized berdazimer gel 10.3% for the treatment of molluscum contagiosum (MC) in grownups and kids aged 1 year or older.
Approval of berdazimer, a topical nitric oxide– launching representative, was based mainly on a 12-week critical stage 3 trial called B-SIMPLE4in which 891 clients with a mean age of 6.6 years (variety, 0.9-47.5 years) were arbitrarily appointed to treatment with berdazimer gel 10.3% or a car gel used in a thin layer to all sores daily. At 12 weeks, 32.4% of clients in the berdazimer group attained total clearance of MC sores compared to 19.7% of those in the car group (P